Search Results - "Zampino, M"

Robotic versus laparoscopic total mesorectal excision for rectal cancer: a comparative analysis of oncological safety and short-term outcomes by Bianchi, P. P., Ceriani, C., Locatelli, A., Spinoglio, G., Zampino, M. G., Sonzogni, A., Crosta, C., Andreoni, B.

“…Background We assessed feasibility, short-term oncologic safety, and short-term outcomes in robotic total mesorectal excision (R-TME) for rectal cancer…”
Get full text

Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial by Louvet, C, Labianca, R, Hammel, P, Lledo, G, Zampino, M G, André, T, Zaniboni, A, Ducreux, M, Aitini, E, Taïeb, J, Faroux, R, Lepere, C, de Gramont, A

“…Gemcitabine (Gem) is the standard treatment for advanced pancreatic cancer. Given the promising phase II results obtained with the Gem-oxaliplatin (GemOx)…”
Get full text

Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: a randomized trial by Biffi, R., Orsi, F., Pozzi, S., Pace, U., Bonomo, G., Monfardini, L., Della Vigna, P., Rotmensz, N., Radice, D., Zampino, M.G., Fazio, N., de Braud, F., Andreoni, B., Goldhirsch, A.

“…Central venous access is extensively used in oncology, though practical information from randomized trials on the most convenient insertion modality and site…”
Get full text

Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA phase 3 randomised trial by Petrelli, F., Rulli, E., Labianca, R., Lonardi, S., Rosati, G., Dotti, K., Ronzoni, M., Pella, N., Pusceddu, V., Banzi, M., Zampino, M.G., Yasmina, M., Marchetti, P., Cantore, M., Zaniboni, A., Rimassa, L., Ciuffreda, L., Ferrari, D., Zagonel, V., Maiello, E., Sobrero, A.

“…Oxaliplatin-based adjuvant chemotherapy is the standard treatment of high-risk colon cancer (CC). A shorter duration (3 months) can achieve a similar outcome…”
Get full text

Preoperative versus postoperative docetaxel–cisplatin–fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial by Fazio, N., Biffi, R., Maibach, R., Hayoz, S., Thierstein, S., Brauchli, P., Bernhard, J., Stupp, R., Andreoni, B., Renne, G., Crosta, C., Morant, R., Chiappa, A., Luca, F., Zampino, M.G., Huber, O., Goldhirsch, A., de Braud, F., Roth, A.D., Pace, U., Cenciarelli, S., Pozzi, S., Bertani, E., Mura, S., Lorizzo, K., Di Meglio, G., Ravizza, D., Boselli, S., Matter, M., Richter, M., Monfardini, S., Dittrich, C., Häfner, M., Clemens, M.

“…Fluorouracil-based adjuvant chemotherapy in gastric cancer has been reported to be effective by several meta-analyses. Perioperative chemotherapy in locally…”
Get full text

Treatments for colorectal liver metastases: a new focus on a familiar concept by Zampino, M.G, Magni, E, Ravenda, P.S, Cella, C.A, Bonomo, G, Della Vigna, P, Galdy, S, Spada, F, Varano, G.M, Mauri, G, Fazio, N, Orsi, F

“…Abstract A major challenge for the management of advanced-colorectal-cancer is the multidisciplinary approach required for the treatment of liver metastases…”
Get full text

Predictive value of circulating tumor-derived DNA (ctDNA) in patients with locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiotherapy (CT-RT): Preliminary results by Ravenda, P., Gregato, G., Rotundo, M., Frassoni, S., Dell'Acqua, V., Trovato, C., Petz, W., Raviele, P. Rafaniello, Bagnardi, V., Bertolini, F., Zampino, M.

Get full text

Aflibercept efficacy according to sidedness, RAS and BRAF mutations. Findings from the VELOUR trial in second line therapy of advanced colorectal cancer patients by Maiello, E., Pomella, V., Wirapati, P., Di Bartolomeo, M., Zampino, M.G., Leone, F., Latiano, T.P., Pietrantonio, F., Ravenda, P.S., Marino, D., Tejpar, S.

Get full text

Carcinoid heart disease in patients with advanced small-intestinal neuroendocrine tumors and carcinoid syndrome: a retrospective experience from two European referral centers by Algeri, L., Falkman, L., Spada, F., Frassoni, S., Bagnardi, V., Boselli, S., Cardinale, D., Zanobini, M., Crona, J., Benini, L., Tamayo, D., Mazzon, C., Gervaso, L., Cella, C.A., Zampino, M.G., Ciardiello, D., Russo, A., Badalamenti, G., Welin, S., Fazio, N.

“…Up to 50% of patients with advanced small-intestinal neuroendocrine tumors (SI-NETs) and carcinoid syndrome (CS) develop carcinoid heart disease (CHD)…”
Get full text

Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial by Lonardi, S, Sobrero, A, Rosati, G, Di Bartolomeo, M, Ronzoni, M, Aprile, G, Massida, B, Scartozzi, M, Banzi, M, Zampino, M G, Pasini, F, Marchetti, P, Cantore, M, Zaniboni, A, Rimassa, L, Ciuffreda, L, Ferrari, D, Barni, S, Zagonel, V, Maiello, E, Rulli, E, Labianca, R

Get full text

Unfavorable carcinoma of unknown primary with a gastrointestinal profile: a retrospective study by Guidi, L., Valenza, C., Battaiotto, E., Trapani, D., Ghioni, M.C., Crimini, E., Boscolo Bielo, L., Venetis, K., Belli, C., Bottiglieri, L., Gervaso, L., Cella, C.A., Ciardiello, D., Spada, F., Benini, L., Adorisio, R., Mane, E., Fazio, N., Guerini Rocco, E., Curigliano, G., Zampino, M.G.

“…Carcinoma of unknown primary (CUP) with a gastrointestinal profile is categorized by the European Society of Medical Oncology (ESMO) guidelines into favorable…”
Get full text

Thromboembolic risk and survival with Khorana score in resected colorectal cancer patients: Subgroup analysis from the adjuvant TOSCA trial by Barni, S., Rosati, G., Zagonel, V., Pella, N., Banzi, M., Zampino, M.G., Di Bartolomeo, M., Rimassa, L., Marchetti, P., Maiello, E., Artioli, F., Ferrari, D., Labianca, R., Bidoli, P., Zaniboni, A., Sobrero, A., Iaffaioli, V., de Placido, S., Frassineti, L.G., Galli, F., Petrelli, F.

Get full text

Prognostic value of neutrophil-lymphocite ratio in resected high risk colorectal cancer: An analysis of adjuvant TOSCA trial by Petrelli, F, Rosati, G, Banzi, M, Zampino, M G, Pella, N, Di Bartolomeo, M, Maiello, E, Bidoli, P, Ferrari, D, Rimassa, L, Labianca, R, Scartozzi, M, Lonardi, S, de Placido, S, Zaniboni, A, Sobrero, A, Frassineti, L G, Silvestris, N, Corsi, D, Galli, F, Barni, S

Get full text

High-risk human papillomavirus in anal squamous cell carcinoma: a ‘conservative’ leading role by Ravenda, P.S., Zampino, M.G., Guerini-Rocco, E., Chiocca, S., Dell’Acqua, V., Trovato, C., Biffi, R., Ribero, D., Spada, F., Cella, C.A., Fazio, N.

Get full text

Enhancement of trans -resveratrol photostability by encapsulation in lipid microparticles: in vitro and in vivo studies by Scalia, S, Zampino, M R, Trotta, V, Bianchi, A

“…Lipid microparticles (LMs) loaded with the antioxidant polyphenol, trans-resveratrol were developed in order to enhance its photostability in topical…”
Get more information

The DISTINCTIVE study: A biologically enriched phase II study of seconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE status - Trial in progress by Ziranu, P., Demurtas, L., Puzzoni, M., Loupakis, F., Daniele, B., Rimassa, L., Bilancia, D., Lonardi, S., Avallone, A., Pella, N., Ferrari, D., Frassineti, L., Beretta, G., Zaniboni, A., Santoro, A., Zampino, M., Sarobba, M., Zagonel, V., Barni, S., Palmieri, G., Labianca, R., Cascinu, S., Scartozzi, M.

Get full text

Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) by Ciardiello, D., Chiarazzo, C., Famiglietti, V., Damato, A., Pinto, C., Zampino, M.G., Castellano, G., Gervaso, L., Zaniboni, A., Oneda, E., Rapisardi, S., Bordonaro, R., Zichi, C., De Vita, F., Di Maio, M., Parisi, A., Giampieri, R., Berardi, R., Lavacchi, D., Antonuzzo, L., Tamburini, E., Maiorano, B.A., Parrella, P., Latiano, T.P., Normanno, N., De Stefano, A., Avallone, A., Martini, G., Napolitano, S., Troiani, T., Martinelli, E., Ciardiello, F., De Vita, F., Maiello, E.

“…The presence of KRASG12C mutation in metastatic colorectal cancer (mCRC) correlates with poor outcome. Although different selective inhibitors are under…”
Get full text

Metformin and risk recurrence in resected stage II/III colon cancer (CC) patients (pts): subgroup analysis from the TOSCA trial by Di Bartolomeo, M., Rosato, G., Banzi, M., Pella, N., Zampino, M.G., Rimassa, L., Maiello, E., Marchetti, P., Lonardi, S., Labianca, R., Zaniboni, A., Sobrero, A., Ferrari, D., Bidoli, P., Iaffaioli, V., De Placido, S., Frassineti, L., Frustaci, S., Nicolini, M., Vernieri, C., Galli, F.

Get full text

FOLFOX4/XELOX in stage II–III colon cancer: early survival data of the Italian Three Or Six Colon Adjuvant (TOSCA) trial by Zaniboni, A., Lonardi, S., Labianca, R., Di Bartolomeo, M., Rosati, G., Ronzoni, M., Pella, N., Banzi, M., Zampino, M.G., Pasini, F., Marchetti, P., Rimassa, L., Maiello, E., Bidoli, P., Cinieri, S., Barni, S., Ciuffreda, L., Beretta, G., Frontini, L., Rulli, E., Sobrero, A.

Get full text

Local recurrence and options of treatment following radical surgery with Total Mesorectal Excision (TME) for rectal cancer by Chiappa, A, Bertani, E, Zbar, A, Venturino, M, Zampino, M, Ferrari, C, Dinang, E.C, Porzio, F.C, Andreoni, B.G

Get full text